Evidence map›Paper›PMID 29075796›Full record

SynthesisDer Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen2018

[Surgical management for early stage gastric cancer].

K Ludwig, D Möller, J Bernhardt

Abstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. [Evidence in minimally invasive oncological gastric surgery].Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen · 2021
    Pooled it
  2. Article
  3. High expression of ZBED1 affects proliferation and apoptosis in gastric cancer.International journal of clinical and experimental pathology · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

K LudwigKlinik für Allgemein‑, Viszeral, Thorax- und Gefäßchirurgie, Klinikum Südstadt Rostock, Südring 81, 18057, Rostock, Deutschland. kaja.ludwig@kliniksued-rostock.de.
D MöllerKlinik für Allgemein‑, Viszeral, Thorax- und Gefäßchirurgie, Klinikum Südstadt Rostock, Südring 81, 18057, Rostock, Deutschland.
J BernhardtKlinik für Allgemein‑, Viszeral, Thorax- und Gefäßchirurgie, Klinikum Südstadt Rostock, Südring 81, 18057, Rostock, Deutschland.
Klinikum Südstadt Rostock · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn the last decade the implementation of the new technique of endoscopic submucosal dissection (ESD) and the rapid progression of laparoscopic gastric cancer (LAG) resection with an adequate lymphadenectomy (LAD) have played an increasing role in the treatment of patients with early stage gastric cancer (EGC).

objectiveA systematic review of the currently available data in the literature was carried out to evaluate the contemporary surgical management for treatment of EGC.

resultsEndoscopic resection (ER) of mucosal T1 gastric cancer (T1m) in accordance with the German guidelines on resection criteria is a widely accepted treatment option, if a definitive R0 resection can be achieved. Excellent en bloc and R0 results in more than 90% of these cases have been shown particularly for ESD. In contrast to T1m gastric carcinomas with a low risk of lymph node metastases (approximately 3%), nodal involvement reaches more than 20% for submucosal infiltrated EGC (T1sm). For this reason, a surgical resection with adequate LAD is further recommended in all cases of non-curative ER or any T1sm gastric cancer. In seven randomized controlled trials and a series of meta-analyses including high-quality non-randomized trials, significant benefits in short-term postoperative outcome have been demonstrated for LAG in comparison to open gastrectomy (OG) in the treatment of EGC. The general morbidity was also significantly lower in LAG than in OG. The 30-day mortality and long-term survival outcome were comparable between the two groups.

conclusionThe use of ESD should be the standard treatment for T1m EGC within the guidelines criteria. For non-curative ESD and T1sm gastric cancer, surgical resection with LAD is recommended. The LAG is a technically safe, feasible, and favorable approach in terms of faster recovery compared to OG. The long-term survival outcome is comparable between LAG and OG for EGC.

Indexed as

Endoscopic Mucosal ResectionGastrectomyStomach NeoplasmsGastric MucosaHumansLymph Node ExcisionRandomized Controlled Trials as TopicRetrospective StudiesTreatment OutcomeEarly gastric cancerGuidelinesLaparoscopic gastrectomyLymphadenectomySubtotal gastric resection

Identifiers

PMID29075796
OpenAlexW2767094454

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.